Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Chasing Survival Benefit With Novel Systemic Strategies in Early-Stage NSCLC

March 11th 2021

Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.

Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer

March 10th 2021

John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.

Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer

March 10th 2021

Theresa Boyle, MD, PhD, discusses the role of concurrent molecular testing in lung cancer.

Second- or Third-Line Canakinumab/Docetaxel Fails to Significantly Improve OS in NSCLC

March 9th 2021

The combination of canakinumab plus docetaxel failed to significantly improve overall survival in patients with locally advanced or metastatic non–small cell lung cancer whose disease has progressed while on, or after, prior platinum-based chemotherapy and a PD-L1 agent, missing the primary end point of the phase 3 CANOPY-2 trial.

FDA Approves Companion Diagnostic for Lorlatinib in ALK+ NSCLC

March 9th 2021

The FDA has approved the VENTANA ALK CDx assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who are eligible to receive treatment with lorlatinib.

WCLC Updates in Small Cell Lung Cancer

March 5th 2021

Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.

WCLC Updates in Locally Advanced NSCLC

March 5th 2021

Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC).

WCLC Updates in Neoadjuvant Therapy for NSCLC

March 5th 2021

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).

Poziotinib Shows Meaningful Activity in EGFR Exon 20–Mutant NSCLC

March 4th 2021

Poziotinib, when given at a daily dose of 16 mg, was found to demonstrate clinically meaningful activity when used in treatment-naïve patients with metastatic non–small cell lung cancer who harbor EGFR exon 20 mutations.

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

March 4th 2021

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

Frontline ICI Therapy Gains Traction Across NSCLC Settings

March 4th 2021

Treatment strategies for patients with advanced-stage non–small cell lung cancer have shifted away from platinum-based doublet chemotherapy and toward combination strategies that include immune checkpoint inhibitors.

Rapid Readouts: Phase 2 CodeBreak 100 Trial

March 4th 2021

Alexander Spira, MD, PhD, FACP, presents slides from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) from CodeBreak 100, the phase 2 trial of sotorasib in KRASG12C-mutated non–small cell lung cancer.

FDA Expands Approval of Lorlatinib for Frontline ALK+ NSCLC

March 4th 2021

The FDA has expanded the indication for lorlatinib to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Spira on the Challenges of Developing NRG1 Fusion–Directed Therapies in NSCLC

March 3rd 2021

Alexander Spira, MD, PhD, FACP, discusses the challenges of developing targeted therapies for patients with NRG1 fusion–positive non–small cell lung cancer.

Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC

March 3rd 2021

Hossein Borghaei, DO, MS, discusses unique characteristics of EGFR exon 20 insertion mutations in non–small cell lung cancer.

Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC

March 2nd 2021

Alexander Spira, MD, PhD, FACP, discusses the efficacy of mobocertinib in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC

March 2nd 2021

Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Merck Withdraws Pembrolizumab Metastatic SCLC Indication in the United States

March 2nd 2021

Merck has withdrawn pembrolizumab from the US market for the treatment of patients with metastatic small cell lung cancer who experienced disease progression on or after platinum-based chemotherapy and at least 1 previous line of treatment.

FDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLC

March 1st 2021

In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic non–small cell lung cancer.

WCLC Updates in Immunotherapy for NSCLC

February 26th 2021

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).